Search

Synthetic oligonucleic acids known as aptamers exhibit remarkable selectivity and affinity for target recognition and binding. Selected via an iterative process known as “selective evolution of ligands by exponential enrichment” (SELEX), aptamers fold into defined 3D conformations to interact with their targets. The incorporation of aptamers as recognition elements has driven notable progress in biosensors, giving rise to the development of aptasensors. Here, the process of aptamer discovery and the development of various types of aptasensors are summarized. The fundamental design principles of aptasensors are elaborated along with the superiority of aptamers compared to antibodies. The various modes employed by aptasensors, such as structure‐switching design, hybridization chain reaction amplification, enzyme‐assisted recycling, and split aptamer design are examined. Further light is shed on the diverse landscape of aptasensors, their adaptability to different analytes aptasensors as well as their potential to propel advancements in modern biosensor technology. As a nucleic acids‐based biosensor platform, aptasensors poise to become a next generation of sensitive and cost‐effective technology to shape the future of molecular recognition in biosensing. [ABSTRACT FROM AUTHOR]

The translation of discoveries on extracellular vesicle (EV) based cancer biomarkers to personalised precision oncology requires the development of robust, sensitive and specific assays that are amenable to adoption in the clinical laboratory. Whilst a variety of elegant approaches for EV liquid biopsy have been developed, most of them remain as research prototypes due to the requirement of a high level of microfabrication and/or sophisticated instruments. Hence, this study is set to develop a simple DNA aptamer-enabled and fluorescence polarisation-based homogenous assay that eliminates the need to separate unbound detection ligands from the bound species for EV detection. High specificity is achieved by immobilising EVs with one set of antibodies and subsequently detecting them with a DNA aptamer targeting a distinct EV biomarker. This two-pronged strategy ensures the removal of most, if not all, non-EV substances in the input biofluids, including soluble proteins, protein aggregates or non-vesicular particles, prior to quantifying biomarker-positive EVs. A limit of detection of 5.0 × 10 6 EVs/mL was achieved with a linear quantification range of 5.0 × 10 8 to 2.0 × 10 10 EVs/mL. Facilitated by a multiple parametric analysis strategy, this aptamer-guided fluorescence polarisation assay was capable of distinguishing EVs from three different types of solid cancer cells based on quantitative differences in the levels of the same sets of biomarkers on EVs. Given the simplicity of the method and its ease of implementation in automated clinical biochemistry analysers, this assay could be exploited for future EV-based continuous and real-time monitoring of the emergence of new macro- or micro-metastasis, cancer progression as well as the response to treatment throughout different stages of cancer management in the clinic., (© 2024 The Author(s). Journal of Extracellular Vesicles published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.)